Intrapleural enzyme therapy (IET) improves outcomes in adult inpatients with complicated parapneumonic pleural effusion or empyema.
The hold followed Intellia’s voluntary pause in response to a grade 4 liver event—a case of Hy’s Law—in the ATTR-CM trial. Shortly after the regulatory hold was implemented, Intellia disclosed that ...
Regenxbio Inc. faces pivotal catalysts in 2026, notably RGX-121's FDA decision and RGX-202 Duchenne data, potentially ...
Postmenopausal women on the GLP-1 medication tirzepatide (Zepbound) for obesity lost more weight if they were also using ...
Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) ...
PPT1 is a recombinant protein used to treat an ultra-rare disease called Batten disease CLN1 for which there is ...
Stanford researchers develop a therapy that regenerates cartilage and blocks osteoarthritis in ageing joints, showing promise for future treatments that restore joint health Stanford researchers have ...
Chronic pain affects more than 50 million Americans, yet for decades, treatment options for pain that persists in the absence ...
Megan Kempf and her husband Kyle are seeking treatment for their two children, who've been diagnosed with a terminal genetic ...
While a majority of the therapies currently in development are life-long treatments, Genespire is taking a different approach ...
Ongoing clinical research at UNC could lead to a first-of-its-kind enzyme replacement therapy for Hunter syndrome, an ultra-rare disorder that causes progressive multisystem disease and neurologic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results